Sign in
Active, not recruitingPhase 3

A study to test trimodulin in adult hospitalized patients with severe pneumonia

Key facts

Who runs it
Biotest GmbH & Co. KGaA
Where
Austria, Belgium, Czechia, France, Germany, Hungary, Ireland, Romania, and Spain56 sites in 9 countriesChoose a country to see its sites
Status
Active, not recruiting
Phase
Phase 3
People taking part
275 people, planned
Started
7 Jun 2023
Expected to end
29 Dec 2028
Type of study
Interventional
Record updated
20 July 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 34 criteriaShow less

Who can take part

  • Written informed consent obtained from subject or legally acceptable/authorized representative (LAR)
  • Hospitalized, adult (≥ 18 years of age) subject (any gender)
  • C-reactive protein (CRP) ≥ 70 mg/L up to 1 calendar day prior to start of treatment with IMP
  • Diagnosis of active community-acquired pneumonia (CAP) before hospital-admission or within 48 hours after admission
  • Radiological (or other imaging technology) evidence consistent with active pneumonia must be available from routine SoC
  • Acute respiratory failure requiring IMV, defining sCAP (Appendix 9: sCAP Diagnostic Criteria According to the ATS/IDSA Guideline)
  • Treatment with IMP must be started between 1 and 24 hours after initiation of IMV
  • Subject must receive SoC treatment for sCAP according to applicable regional and global sCAP guidelines

Who cannot take part

  • Selective IgA deficiency with known antibodies to IgA
  • Treatment with > 1 g/kg body weight of polyvalent immunoglobulin preparation in total during the last 21 days before start of IMP treatment
  • Treatment with fluoroquinolone preparations, during the last 2 days before start of IMP treatment
  • Hematopoietic stem cell transplantation within 1 year, or previous lung transplantation
  • Treatment with investigational medications procedures not according to SoC of the trial site , due to participation in another interventional clinical tria within 30 days before start of IMP treatment or previous IMP treatment with IMP in this clinical trial
  • Subjects discharged from hospital within the previous 14 days
  • Thromboembolic events (TEEs) caused by other reasons than the current sCAP (e.g., cerebrovascular accidents, transient ischemic attack, myocardial infarction, pulmonary embolism, and deep vein thrombosis) within 3 months before start of IMP treatment.. unless the risk for further TEEs can be adequately managed with standard prophylaxis or treatment
  • Pre-existing severe lung diseases concomitant to current sCAP (e.g., subjects with active tuberculosis, or active lung cancer)
  • Life expectancy of less than 90 days, according to the investigator’s clinical judgment, because of medical conditions related neither to sCAP nor to sCAP-associated septic conditions
  • Pre-existing hemolytic disease
  • End-stage renal disease (ESRD) or known primary focal segmental glomerulosclerosis (FSGS)
  • Pre-existing decompensated heart failure (New York Heart Association class III–IV)
  • Pre-existing severe hepatic cirrhosis, (Child Pugh score ≥ 10 points), or severe hepatic impairment (Child Pugh score ≥ 10 points), or hepatocellular carcinoma
  • Known intolerance to proteins of human origin or known allergic reactions to any of the components of trimodulin / placebo
  • Severe neutropenia (neutrophil count <500/mm³) per most recent test performed up to 1 calendar day prior to start of IMP treatment
  • Thrombocytopenia (platelet count <30,000/mm³) per most recent test performed up to 1 calendar day prior to start of IMP treatment
  • Hemoglobin (Hb) < 7 g/dL hours per most recent test performed up to 1 calendar day prior to start of IMP treatment
  • Severe renal impairment, estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m² per most recent test performed up to 1 calendar day prior to start of IMP treatment (details in Appendix 2: Estimated Glomerular Filtration Rate).*), unless the subject is already on dialysis or continuous replacement therapy
  • For an incapacitated subject: any indication that the subject’s presumed will would be against inclusion in the trial
  • Pregnant or lactating women
  • Morbid obesity with high body mass index (BMI) ≥ 40 kg/m2, or malnutrition with low BMI < 16 kg/m2
  • Employee or direct relative of an employee of the CRO, or the trial site, if employee is directly involved in the trial or otherwise in a dependent relationship with the site staff
  • Persons, subject to legal protection measures, if applicable according to local laws
  • Subjects of childbearing potential not willing to use reliable contraceptive measures during the trial and for 15 weeks after the last IMP treatment
  • Subjects on extracorporeal membrane oxygenation (ECMO) at start of IMP treatment
  • Suspected hospital-acquired pneumonia (HAP) including ventilator associated pneumonia (VAP)

This trial has no sites in United States.

It has sites in 9 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

To assess the efficacy of trimodulin based on 28-day all-cause mortality to demonstrate superiority to treatment with placebo

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects with severe community-acquired pneumonia (sCAP)
Record updated
20 July 2026